Document is current

Article History

Received: 16 June 2025

Accepted: 1 August 2025

First Online: 29 August 2025

Declarations

:

: Sevim Bavbek has given lectures at meetings supported by AstraZeneca, GSK, and Novartis, and reports receipt of advisory board fees from AstraZeneca, GSK, and Novartis. Mona Al-Ahmad has received lecture and advisory board honoraria from AstraZeneca, GSK, Novartis, and Sanofi. Hala Samaha has received lecture and advisory board honoraria from AstraZeneca, GSK, and Sanofi. Pooran Chand Kathuria has no conflicts of interest to report. Patricia Fernandez reports having been a speaker for AstraZeneca, GSK, Sanofi, and Teva, and participated in advisory boards with AstraZeneca, GSK, and Sanofi. Nasser Al Busaidi has received lecture and advisory board honoraria from AstraZeneca, GSK, and Sanofi. Tayseer Ibrahim has received lecture honoraria from AstraZeneca, GSK, and Sanofi. Bassam Mahboub has received lecture and advisory board honoraria from AstraZeneca, GSK, and Sanofi. Seema Haider and Gur Levy are employed by and hold financial equities in GSK. Saeed Noibi is employed by GSK. Riyad Omar Al-Lehebi has given lectures at meetings supported by AstraZeneca, Boehringer Ingelheim, GSK, and Sanofi, and received advisory board fees from GSK.

: The study protocol was reviewed and approved by an institutional review board, and the study was conducted in accordance with the International Council on Harmonisation, Good Pharmacoepidemiology Practice, Good Clinical Practice, and all applicable patient privacy requirements and country-specific requirements relevant for an observational study. Data were collected from existing medical records and ethical committee reviews were conducted for all included countries. Informed consent to participate was obtained for patients in countries where a waiver for informed consent was not requested or granted. The data collected were anonymized and non-identifiable.